**United States RNAi Therapeutics for Rare Genetic Disorders Market to Reach USD 0.70 Billion by 2034 as Precision Gene-Silencing Therapies Gain Momentum**
According to a report by Intel Market Research, the United States RNAi Therapeutics for Rare Genetic Disorders Market was valued at **USD 0.36 billion in 2025** and is projected to reach **USD 0.70 billion by 2034**, registering a **CAGR of 8.9%** during the forecast period. Market growth is driven by increasing federal funding for orphan disease research, expanding FDA approvals for RNAi-based therapies, and rising demand for precision medicines targeting rare genetic disorders. Advancements in siRNA technologies and innovative delivery platforms, including lipid nanoparticles (LNPs) and GalNAc conjugates, are improving treatment efficacy, safety, and targeted gene silencing. Growing clinical success, strategic collaborations, expanding R&D investments, and scalable manufacturing technologies are further accelerating commercialization. As precision medicine adoption increases and orphan drug incentives continue to support innovation, RNAi therapeutics are expected to play a vital role in treating underserved rare disease populations.
**Download Sample Report* [https://www.intelmarketresearch.
